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Abstract
Studies that compare the treatment response of patients diagnosed as primary affective disorder or schizoaffective disorder are reviewed. Although relatively few controlled or uncontrolled studies of the chemotherapy of schizoaffective disorders have been conducted, available evidence suggests that: (1) lithium carbonate is effective in the initial treatment of both schizoaffective mania and mania; (2) antidepressants alone, neuroleptics alone, or their combination can be effective in the initial treatment of both schizoaffective depression and primary depression; and (3) prophylactic administration of lithium carbonate may reduce the frequency and duration of relapse in both schizoaffective manic and schizoaffective depressed patients. Thus, treatment studies indicate that the schizoaffective disorders are very similar to the primary affective disorders with regard to response to pharmacologlc treatment. Evidence from this laboratory that schizoaffective manic patients respond more slowly than manic patients to lithium or neuroleptic treatment is presented.
The controversy as to whether schizoaffective disorder is a subtype of schizophrenia (American Psychiatric Association 1968; Detre and Jarecki 1971) , a form of primary affective illness (Pope and Lipinski 1978) , or a unique syndrome with a unique etiology, biological concomitants, genetic predispositions, and treatment outcome (American Psychiatric Association 1980; Klein et al. 1981) has been reviewed in other articles in this issue from the vantage point of epidemiology, family history, genetics, and biological studies. Clinical response to somatic treatment may also be of value in clarifying the relationship between the major psychoses. For example, it has been suggested that a good therapeutic response to lithium or antidepressant drug treatment may be a criterion for differentiation of primary affective illness from other types of psychiatric illness (Forssman and Walinder 1970; Sicignano and Lichtenstein 1978) . Other investigators have discussed and usually rejected this possibility (Noack and Trautner 1951; Kingstone 1960; Wharton and Fieve 1966; Goodwin, Murphy, and Bunney 1969; Shopsin, Johnson, and Gershon 1971; Dunner and Fieve 1978; Schou 1979; Braden et al. 1982) . Should established therapies of affective disorders fail to be of clinical value in the treatment of schizoaffective depression, schizoaffective mania, or both, this would provide some indication that the latter are either not related to affective disorders or that they are -very distinct subtypes of affective disorders with an important discontinuity in the area of treatment response. However, prophylactic effects of somatic treatment on affective and schizoaffective disorders might be more informative because of the greater likelihood that a common etiological factor might have to be present for a prophylactic effect to be manifest.
We will review studies which compare various effects of somatic treatment in schizoaffective and major affective disorders: (1) the effectiveness of various drug treatments in the initial treatment of schizoaffective mania and depression; (2) prophylactic treatment of schizoaffective and primary affective disorders; (3) differences in drug Reprint requests should be sent to Dr. P.J. Goodnick, Illinois State Psychiatric Institute, 1601 W. Taylor St., Chicago. 1L 60612.
response between schizoaffective and primary affective disorders; and (4) the relationship of various diagnostic criteria for schizoaffective disorder to drug response. The treatment of schizoaffective disorders with lithium was recently reviewed by Delva and Letemendia (1982) and Fieve and Goodnick (1983) .
Initial Treatment of Schizoaffective Mania
The initial treatment of schizoaffective mania and mania with lithium, neuroleptics, or the combination has been intensively investigated. There are 14 published studies other than case reports, six double-blind and eight open, of the effect of these drug treatments in schizoaffective mania. Table 1 lists each of these studies, along with a description of the subjects, diagnostic criteria, response measures, drugs and dosages, duration of treatment, and an overall summary of the clinical outcome.
Several problems complicate the interpretation of these studies. Firstly, before the development of the research diagnostic criteria (RDC) by Spitzer, Endicott, and Robins (1978) , there was even greater ambiguity and variation in the diagnostic criteria for all three diagnostic categories than currently exists. Some studies initially included schizoaffective patients with schizophrenic patients and only later considered both groups separately. This raises the possibility that the schizoaffective patients included were those whose symptomatology was closer to schizophrenia than to affective illness. Studies designed to contrast the response of schizoaffective with either primary affective disorder or schizophrenia are more likely to produce reliable comparisons. Secondly, many studies (Rice 1956; Wharton and Fieve 1966; Gottfries 1968; Aronoff and Epstein 1970; Megrabyan et al. 1979; Pope et al. 1980) did not apply rating scales to m easure clinical change. However, we have opted to include their results in this review when we consider the global assessments of all studies. Finally, in all but two studies, treatment periods were 1 month or less which may be inadequate to assess clinical efficacy (see below).
Despite the difficulties cited above, surprising agreement in the results is evident. First, the mean rate of at least partial response to lithium carbonate treatment in schizoaffective mania in all 14 studies (76.5 ± 18.2 percent, n = 290) is similar to that in manic patients (93 ±7.7 percent, n = 463). The only study (Pope et al. 1980 ) that directly compared lithium responsiveness in mania and schizoaffective mania diagnosed by RDC reported a 95 percent rate of partial improvement for schizoaffective mania and 100 percent for mania. Three studies Biederman, Lerner, and Belmaker 1979; Carman, Bigelow, and Wyatt 1981 ) that used both the RDC criteria and a double-blind research design found the incidence of partial symptom improvement in schizoaffective mania to vary from 60 percent (Carman, Bigelow, and Wyatt 1981) to 100 percent , but no manic patients were included. The most recent such study (Braden et al. 1982) found no differences among manic, schizoaffective manic, and schizophrenic patients (modified RDC) in final global ratings following treatment with lithium or chlorpromazine. However, when overactive patients were excluded, schizophrenic patients did more poorly on both drugs.
The proportion of schizoaffective manic patients who responded to lithium treatment (36-100 percent, n = 94) was higher than that in schizophrenics (0-40 percent, n -113) in all investigations which have included both diagnostic groups (Rice 1956; Gottfries 1968; Small et al. 1975; Alexander, Van Kammen, and Bunney 1979; Hirschkowitz et al. 1980; Pope et al. 1980; Carman, Bigelow, and Wyatt 1981) . Four of these studies diagnosed patients according to RDC; one (Hirschkowitz et al. 1980 ) was open and the other three (Small et al. 1975; Alexander, Van Kammen, and Bunney 1979; Carman, Bigelow, and Wyatt 1981) were double-blind. The open study showed only a slightly greater rate of response in the schizoaffective manics (36 percent) than in the schizophrenics (25 percent); the doubleblind studies demonstrated that lithium was much more effective in the schizoaffective manics (87 ± 23 percent, n ~ 12) than in the schizophrenics (34 ± 14 percent, n = 30).
Extent of Treatment Response. Although the percentages of schizoaffective manic and manic patients who show partial improvement in response to lithium are comparable, available evidence suggests that schizoaffective manic patients are less likely than manic patients to achieve nearly complete remission of symptoms in response to lithium during the period of observation (Rice 1956; Gottfries 1968; Zall, Therman, and Myers 1968; Aronoff and Epstein 1970; Johnson 1970; Pope et al. 1980) . These studies reported that marked improvement or total symptom elimination by lithium occurred in 73 ± 18 percent (n «= 167) of manic patients and 26 ± 29 percent (n -107) of schizoaffective patients. Two controlled studies (Aronoff and Epstein 1970; Response of Thought Disorder to Lithium. An important consideration is the differential response of particular symptoms to lithium treatment in the schizoaffective manic patients. There have been three (Small et al. 1975; Biederman, Lerner, and Belmaker 1979; Carman, Bigelow, and Wyatt 1981) doubleblind, placebo-controlled investigations of lithium carbonate in the treatment of schizoaffective manic patients maintained on neuroleprics, and one such study in which lithium alone was used. Three of these studies Biederman, Lerner, and Belmaker 1979; Carman, Bigelow, and Wyatt 1981) Zall, Therman, and Myers (1968) , found lithium was effective only in treating affective symptoms, in a high proportion of schizoaffective manic patients. Lithium had a beneficial effect on thought disorder in only 0-10 percent of schizoaffective manic patients.
Response of Hallucinations to Lithium. Auditory hallucinations have been reported to respond to lithium (Forssman and Walinder 1970; Freedman and Schwab 1978; Braden and Quails 1979; Wagemaker, Lippmann, and Bryant 1979) . Two controlled studies have used the Brief Psychiatric Rating Scale (BPRS; Overall and Gorham 1962) to evaluate changes in hallucinations in schizoaffective manic patients. The study that used RDC criteria found lithium to have a slight advantage over placebo (Biederman, Lerner, and Belmaker 1979) ; the other showed no difference (Small et al. 1975 ).
Response of Paranoia and Delusions to Lithium. There are some data on the effectiveness of lithium treatment of paranoid delusions and unspecified psychotic symptoms in schizoaffective manic patients. As with hallucinations, case reports show almost total remission of these symptoms in schizoaffective patients treated with lithium alone (Forssman and Walinder 1970; Freedman and Schwab 1978; Braden and Quails 1979; Wagemaker, Lippmann, and Bryant 1979) . Alexander, Van Kammen, and Bunney (1979) and Carman, Bigelow, and Wyatt (1981) reported results of double-blind, placebo-controlled studies which found significant improvement in "psychosis" in schizoaffective manics (RDC) after lithium therapy. Two further studies (Small et al. 1975; Biederman, Lerner, and Belmaker 1979) that presented change in BPRS ratings during lithium treatment found no significant change in unusual thinking but significant improvement in suspiciousness. Biederman, Lerner, and Belmaker (1979) used the RDC, whereas Small et al. (1975) used Feighner criteria for defining mania but used their own criteria to define schizoaffective mania. In a study of schizoaffective manics diagnosed by the RDC (Biederman, Lerner, and Belmaker 1979), lithium was significantly better than placebo on BPRS subscales. Thus, the three studies that applied the RDC for schizoaffective mania described significant lithium-induced improvement in psychotic symptoms, whereas the one study that did not found no response.
Comparison of Lithium and Neuroleptic Response. The relative efficacy of lithium carbonate and neuroleptics, or their combination, in the treatment of mania and schizoaffective mania has been examined in only five studies (Shopsin, Kim, and Gershon 1971; Johnson et al. 1971; Klett 1972a, 1972k; Braden et al. 1982) . Shopsin, Kim, and Gershon (1971) reported that chlorpromazine (CPZ) treatment produced greater improvement in 15 BPRS items in a group of schizoaffective (n = 4) and schizophrenic (n = 17) patients than did lithium. These differences reached statistical significance for the BPRS items somatic concern, grandiosity, and suspiciousness. Johnson et al. (1971) reported the results of a single-blind trial of CPZ or lithium in 21 manic and 13 schizoaffective manic patients. Manic patients had an overall favorable response to both CPZ and lithium; CPZ was superior only for the mannerisms scale. However, schizoaffective patients significantly responded to CPZ but not to lithium. The two medications produced equal improvement in psychotic symptoms, i.e., conceptual disorganization, suspiciousness, hallucinations, and unusual thoughts. Klett (1972a, 1972b) reported results of the Veterans Administration-National Institute of Mental Health collaborative study of acute treatment of manic (n -255) and schizoaffective manic illness (n = 83). Lithium and CPZ were equally effective in both groups overall, but CPZ produced more rapid sedation in those patients in both diagnostic groups who were "highly active." Furthermore, in the "highly active" schizoaffective subgroup, CPZ produced greater benefit than lithium in BPRS conceptual disorganization, suspiciousness, and hallucinatory behavior. Pope et al. (1980) , in the only study using RDC, reported moderate improvement or better in manic patients following either lithium alone or lithium plus neuroleptic in all 30 patients studied. Such a response was found in two of three manic patients receiving neuroleptic alone. The comparative effectiveness of drug treatments in schizoaffective patients was as follows: lithium alone (95 percent, n = 20), lithium plus neuroleptic (86 percent, n " 14), and neuroleptic alone (83 percent, n = 12). Here, as before.
when schizoaffective patients were diagnosed by specific criteria, their response was similar to that found for manic patients, i.e., there is little difference in therapeutic effect between lithium alone, neuroleptic alone, or lithium plus neuroleptic. Braden et al. (1982) also found that aside from an initial advantage for chlorpromazine over lithium in overactive patients, lithium and chlorpromazine produced similar clinical improvement.
Latency to Response in Schizoaffectives and ManicDepressives. There is some evidence to suggest that manic patients respond more rapidly to lithium than do schizoaffective manic patients. The two studies showing the greatest discrepancy in response rates to lithium between manic and schizoaffective manic patients had the shortest treatment periods. Aronoff and Epstein (1970) , with only 2 weeks of treatment, reported 100 percent of 12 manic patients but only 67 percent of 6 schizoaffective manic patients responded; Johnson (1970) , with a 3-week duration of therapy, found improvement in 95 percent of 19 manic but only 45 percent of 11 schizoaffective manic patients. Of the more recent studies, the one with the lowest rate of response to lithium in schizoaffective manic patients (36 percent) used only a 2-week period of drug administration (Hirschkowitz et al. 1980) . Of the 10 studies indicating duration of treatment (table 1) , the mean proportion of schizoaffective manic patients showing improvement in the five studies with a treatment duration of > 4 weeks was 85 ± 9 percent (n = 56). The five studies with a treatment period of < 3 weeks reported a lower percentage of response, 52 ± 34 percent (n = 41). These rates were nearly significantly
The correlation between treatment weeks and percentage of schizoaffective patients responding (r -0.62, df = 8, p < .10) was also nearly significant. 1983) . Preliminary results will be reported here. Seventy-one patients, subdivided into both major (mania, n -41, and schizoaffective mania, n -30) and minor (mania: psychotic, n = 23, and nonpsychotic, n = 18; schizoaffective mania: mostly affective, n = 17, and mostly schizophrenic, n = 13) categories, were diagnosed according to the RDC, and by the presence or absence of delusions, hallucinations, or both. The dose of lithium was 1,500-1,800 mg/day in both diagnostic groups, regardless of whether neuroleptic drugs were also administered. The peak daily dose of neuroleptic in chlorpromazine equivalents was 1,200-1,400 mg/day in both diagnostic groups, regardless of whether lithium was also given. greater than baseline), and total BPRS scores decreased 21.7 points (74 percent less than baseline).
Rate of Response. A significant difference in the duration of treatment needed to reach 80 percent of maximal improvement was found for the two diagnostic groups. Overall, schizoaffective patients required 61.6 ± 31.5 days to achieve this degree of improvement, whereas bipolar manic patients required only 26.6 ± 18.9 days (p < .001). Thus, it took about twice as long for each treatment to achieve the same degree of effectiveness in the schizoaffective manic patients compared to the manic patients.
Neurotoxidty. Johnson (1970) and Shopsin, Johnson, and Gershon (1971) concluded that lithium was more likely to produce neurotoxicity in schizophrenic and schizoaffective patients than in manic patients. West and Meltzer (1979) also concluded that acute manic, schizophrenic, and schizoaffective patients were at greater risk for lithium-induced neurotoxicity than chronically ill patients. West (1982) suggested that the relevant issue for vulnerability to neurotoxicity was not the diagnosis of schizophrenia or schizoaffective disorder, but rather duration of illness; acutely ill patients are more likely to become neurotoxic during lithium treatment than chronically ill patients.
Conclusion. In conclusion, lithium appears to be equally effective in the acute treatment of schizoaffective manic and manic patients diagnosed according to the RDC. Lithium alone and neuroleptics alone produce comparable overall improvement and are effective in the treatment of nonaffective and affective symptoms in both schizoaffective manic and manic patients. Those studies which have reported that neuroleptics are more effective than lithium in the treatment of schizoaffective patients have used criteria other than the RDC. Schizoaffective patients were found to require a significantly longer period of drug administration than manic patients to achieve comparable remission. Both disorders responded to treatment with lithium, neuroleptics, and combined treatment. Thus, consideration of data on treatment of schizoaffective mania and mania suggests there is no reason to reject the hypothesis that schizoaffective disorder, as defined by RDC, is a variant of bipolar disorder. However, the much longer period which schizoaffective patients require to respond to medication compared to manic patients may be related to important differences in severity of illness or possibly underlying biology.
Initial Treatment of Schizoaffective Depression
There are 12 published controlled studies (eight double-blind and four open) concerning the efficacy of pharmacotherapy in the treatment of schizoaffective depression. Table 3 provides a description of the subjects, diagnostic criteria, response measures, drugs and dosages, duration of treatment, and an overall summary of the clinical outcome.
Interpretation of these results is complicated by the same factors discussed above with reference to the drug treatment studies of schizoaffective manic patients: problems in diagnosis, lack of application of standard measures of clinical change, and variability in treatment periods. Antidepressant Response. Four studies (Angst 1961; Greenblatt, Grosser, and Wechsler 1962; Hordern et al. 1963 ; Avery and Winokur 1977) have compared the response of major and schizoaffective depression to antidepressants. The proportion of patients who showed improvement were: bipolar depressives (54 ± 18 percent, n = 64), unipolar depressives (59 ± 18 percent, n " 237), and schizoaffective depressives (54 ± 18 percent, n «« 49). Three studies that used the RDC-one retrospective (Avery and Winokur 1977), one double-blind (Brockington et al. 1978) , and one open (Brockington, Kendell, and Wainwright 1980)-report a low rate of response of schizoaffective patients to antidepressant drugs (37 ± 8 percent, n = 150). These results are generally supported by another double-blind study (Prusoff et al. 1979 ) which evaluated the effect of adding amitriptyline to neuroleptics in 40 depressed schizophrenics who were diagnosed according to DSM-III, but who would probably meet the RDC for schizoaffective depression. Little significant improvement was found. Two articles (Greenblatt, Grosser, and Wechsler 1962; Hordern et al. 1963) published data comparing psychotic depression and schizoaffective depression. The rate of response of schizoaffective depressed patients (23-50 percent, n = 35) was slightly lower than that of psychotic depressed patients (30-67 percent, n -33). These results for delusional depression are comparable to other more recent reports (Glassman, Kantor, and Shostak 1975; Nelson and Bowers 1978; Avery and Lubriano 1979) . Neuroleptic Response. Brockington et al. (1978) and Brockington, Kendell, and Wainwright (1980) examined the effect of neuroleptics alone, or in combination with antidepressants, in the acute treatment of schizoaffective depression. The 1978 Lithium Response. Five studies (Small et al. 1975; Alexander, Van Kammen, and Bunney 1979; Hirschkowitz et al. 1980; Carman, Bigelow, and Wyatt 1981) have examined the response of schizoaffective depressed patients to lithium carbonate. Lithium appears to have comparable modest efficacy for both schizoaffective depression and some forms of schizophrenia. All but one of these studies (Small et al. 1975 ) applied RDC. All but one (Hirschkowitz et al. 1980) were double-blind. It should be noted that Hirschkowitz et al. (1980) did not separately describe the clinical response of schizoaffective manic and schizoaffective depressed patients to lithium; therefore, it is not possible to evaluate fully the results of this study. The proportion of schizophrenic and schizoaffective patients who responded to lithium in the other four reports was 36 ± 8 percent (n -5) and 38 ± 10 percent (n = 30), respectively. Van Kammen, Alexander, and Bunney (1980) reported that 6/10 (60 percent) of schizoaffective depressed patients receiving lithium had a reduction of at least 1.5 on the depression rating on the Bunney-Hamburg scale.
Electroshock Response. Seven reports (Greenblatt, Grosser, and Wechsler 1962; Hordern et al. 1963; Folstein, Folstein, and McHugh 1973; Wells 1973; Avery and Winokur 1977; Brockington, Kendell, and Wainwright 1980; Ries et al. 1981) present data on the efficacy of electroconvulsive therapy (ECT) in the treatment of schizoaffective depression. Two of these (Greenblatt, Grosser, and Wechsler 1962; Avery and Winokur 1977) compared the efficacy of ECT in schizoaffective depression and major depression. Both studies demonstrated similar rates of response in bipolar depression (43-80 percent, n = 19), unipolar depression (52-89 percent, n °= 132), and schizoaffective depression (41-80 percent, n = 27). Two studies that did not use the RDC (Greenblatt, Grosser, and Wechsler 1962; Hordern et al. 1963 ) report a higher rate of response to ECT in schizoaffective depression (80-100 percent) than do studies that used the RDC (Avery and Winokur 1977; Brockington, Kendell, and Wainwright 1980) (41-62 percent). These four studies report that ECT is more effective than pharmacotherapy in the treatment of schizoaffective depression. A similar conclusion has been reached with regard to psychotic depression. Overall, 54 ± 12 percent (n =• 56) markedly improved following ECT, but only 30 ±6 percent (n -75) after antidepressants. Three studies (Folstein, Folstein, and McHugh 1973; Wells 1973; Ries et al. 1981 ) noted that schizoaffective patients responded better to ECT than did schizophrenics, and that the response rate in the schizoaffectives was comparable to that usually reported in affective patients. Thus, the response to drug treatment and ECT of schizoaffective depressed patients is not significantly different from that of major depression, very close to that found in delusional depression, but significantly better than that of schizophrenics. ECT is superior to antidepressant drugs but, even then, the maximal percentage of RDC schizoaffective depressed patients responding is approximately 50 percent. Few schizoaffective depressed patients respond to either antidepressant alone or lithium alone.
A Study of Symptom Response in Schizoaffective Depression. The comparative effectiveness of drug treatment of schizoaffective depression and major depression on specific symptoms was considered in a retrospective analysis from this center. Fifty-six patients with major depressive disorder and 44 patients with schizoaffective depression, diagnosed according to the RDC, were included in an analysis of symptom change during the course of treatment with neuroleptics or antidepressants. A criterion for inclusion in this analysis was a pretreatment GAS rating from the SADS of 60 or below. A further requirement was a 3-week treatment period with a neuroleptic at a dose of at least 600 mg equivalent of chlorpromazine or 150 mg imipramine, desipramine, amitriptyline, or maprotiline, of 75 mg of nortriptyline, and of 300 mg of trazodone. The patients were evaluated weekly by a trained psychologist with the SADS-C. Symptom response was measured by change in the GAS, depressive syndrome, auditory hallucinations, delusions of reference and persecution, and thought disorder; all of these are subscales of the SADS-C. Furthermore, a computergenerated Hamilton depression total based upon the SADS-C was also used for outcome measurement.
Analysis of outcome (table 4) yielded few differences in response between diagnostic groups. Schizoaffective depressed patients had greater improvement than depressed patients in auditory hallucinations (F = 8.55, df -1, p = .004), but the greater improvement was due to greater baseline severity (F -23.07, df -1, p -.0001). However, the patients showing the greatest improvement in the Hamilton depression score derived from the SADS were the depressed patients treated with antidepressants (F -3.76, df -1, p = .05).
Examination of the rating change for each scale by diagnostic group and treatment condition revealed other important differences (table 4). In the depressed group, there was a clear difference in the effect of the treatment on specific symptoms. Thus, total Hamilton and SADS depressive syndrome scores improved after antidepressants but not antipsychotics; auditory hallucinations, and delusions of reference and persecution improved with neuroleptic treatment but not with antidepressant treatment. In the schizoaffective depressed group, antipsychotics produced slightly more improvement than antidepressants in GAS, auditory hallucinations, and delusions of reference and persecution scores. Neuroleptics produced significant improvement in total Hamilton score in schizoaffective depressed patients, but antidepressant therapy led to no significant changes.
These results are in agreement with previous findings. Angst (1961) ; Greenblatt, Grosser, and Wechsler (1962); and Hordern et al. (1963) reported schizoaffective depressed patients had a slightly poorer response to antidepressants than did depressed patients, while Avery and Winokur (1977) found no significant difference between the two groups (RDC criteria). Our finding that depressed patients treated with antidepressants did slightly better than those treated with neuroleptic treatment are in accord with the above. Furthermore, our finding that neuroleptic treatment produces somewhat better results than antidepressants in schizoaffective depressed patients agrees with that of Brockington et al. (1978 Brockington et al. ( , 1980 , who showed that chlorpromazine more frequently produced improvement than amitriptyline; 54-55 percent of schizoaffective depressed patients responded to chlorpromazine and only 33-46 percent responded to amitriptyline.
Prophylaxis of Schizoaffective Disorders
Ten studies have addressed the prevention of recurrences of schizoaffective illness, whether manic or depressed type. Table 5 lists each study, along with subject description, diagnostic criteria, response measures, dose and duration of administered medication, experimental conditions, and results. ii The 10 studies compare results on 220 schizoaffective patients, diagnosed according to various diagnostic criteria, with that of 574 manic-depressive and 148 patients with recurrent depression. Only 1 of the 10 studies was double-blind; it included only six schizoaffective subjects. All 10 studies used lithium carbonate for prophylaxis.
Some of the earlier studies report a better response in bipolar patients (67-72 percent, n = 365) than in schizoaffective manic patients (40-53 percent, n = 97) (Angst et al. 1970; Hofmann et al. 1970; Klett 1973, 1974) . The finding of Angst et al. (1970) that lithium significantly reduced the frequency of episodes in schizoaffective patients and the report of Klett (1973, 1974) that the relapse rate of schizoaffective patients increased to 60 percent after the discontinuation of lithium strongly indicate that lithium was exerting a prophylactic action, even in the absence of a placebo control. Recent studies, which have had equal numbers of subjects in each diagnostic group and clearly defined criteria for diagnosis, have reported more equivalent efficacy in both diagnostic groups than the earlier ones. Thus, the studies of Rosenthal et al. (1980) and Sarantidis and Waters (1981) , which used the RDC, found that schizoaffective patients remained as well on lithium as did manic patients. Rosenthal et al. (1980) compared the probability of nonrelapse in manic and schizoaffective manic patients at weeks 16, 52, and 104 of lithium treatment. After 1 year of treatment, schizoaffective patients were 13 percent more likely to be in remission than manic patients; after 2 years, schizoaffective patients were 6 percent less likely than manic patients to still be in remission. Sarantidis and Waters (1981) used length of hospitalization as the criterion for lithium response. The proportion of patients having at least a fair lithium response was slightly greater in schizoaffective manic patients (89 percent) than in manic patients (78 percent). The decrease in days spent in the hospital compared to the year before beginning prophylaxis with lithium was 62 percent for the manic patients and 76 percent for the schizoaffective patients.
Thus, lithium carbonate, administered at the usual doses needed to achieve a plasma concentration of 0.6-1.0 mEq/1, appears to be effective in preventing recurrences of schizoaffective disorder in up to 90 percent of patients.
Somatic Treatments of Schizoaffective Disorders
Other than Lithium, Neuroleptlcs, and Conventional Antidepressants Apomorphine and Bromocriptine. Dopamine agonists in low doses have been administered to psychotic patients on the premise that stimulation of dopamine autoreceptors can inhibit the synthesis and release of dopamine (Meltzer 1982) . Recent studies (Corsini et al. 1981; Meltzer et al. 1983 ) have suggested that low dose dopamine agonist treatment may be more effective in the treatment of schizoaffective patients than schizophrenics. Corsini et al. (1981) administered 1 mg of apomorphine intramuscularly to 36 patients originally diagnosed as schizophrenic. Eighteen of these patients showed either improvement of at least 75 percent in baseline Brief Psychiatric Rating Scale (BPRS) scores (responders) or no improvement (nonresponders). Diagnosis of these patients according to the RDC indicated that seven of the nine responders fulfilled criteria for schizoaffective disorder, manic type. Only one of the nine nonresponders was schizoaffective (depressed type). . Meltzeretal. (1983) administered bromocriptine (0.5-6.0 mg/day) to seven schizophrenic and two schizoaffective patients after a 2-4 week placebo period. One of the schizoaffective patients showed marked improvement and the other moderate, as contrasted to mild improvement in three of the seven schizophrenic patients. The other four worsened following initial modest improvement. The schizoaffective depressed patient who responded best demonstrated marked improvement in both affective and psychotic symptoms on 0.25-0.50 mg/day for 3 weeks; a drug response was suggested by the relapse and restoration of improvement when the medication was first withdrawn and then reinstated.
Des-Tyr-y-Endorphln. The effect of des-tyrosine-y-endorphin (DTyE) has been extensively investigated in schizophrenic and schizoaffective patients (Verhoeven et al. 1981; Meltzer et al. 1982; Van Praag et al. 1982) . Verhoeven et al. (1981) and Van Praag et al. (1982) administered DTyE in doses of 1 mg intramuscularly for 8-10 days. Nine of 23 patients had a slight to moderate response; a marked response was observed in seven. All patients were also being treated with neuroleptics which had not been effective by themselves. The schizoaffective patients (n •» 4) responded considerably less well than the chronic schizophrenic patients. Meltzer et al. (1982) conducted an open study of DTyE in which the drug was administered for 12 days in doses ranging from 1 to 10 mg/day. The study group included seven schizophrenic patients and one schizoaffective manic-mostly schizophrenic patient according to RDC. As in the previous study, the schizoaffective patient did much less well than the schizophrenic patients. Three instances of moderate or marked improvement and three of minimal improvement were found in the seven schizophrenic patients. There are no data available on the effect of DTyE in patients with RDC diagnoses of major affective disorder. The data for the effectiveness of DTyE in schizophrenia and its ineffectiveness in schizoaffective disorders are far from conclusive.
L-Tryptophan.
The "permissive" hypothesis of affective disorders is based upon a serotonin deficiency leading to vulnerability to develop either mania or depression (Prange et al. 1973) . For this reason, the serotonin precursor, L-tryptophan, has been used for both the treatment and prevention of manic-depressive disorder (Van Praag 1982) . A recent study compared the clinical response to L-tryptophan plus lithium versus placebo plus lithium in manic and schizoaffective manic patients (Brewerton and Reus 1983) . A double-blind placebo-controlled study with a 21-day drug treatment period was conducted. The patient sample included nine patients with a diagnosis of bipolar disorder and seven with a diagnosis of schizoaffective disorder, according to DSM-III. All patients had Manic State Rating Scale (Beigel, Murphy, and Bunney 1971) scores above 24 at baseline. L-Tryptophan was administered in increasing doses over 6 days to a maximum dose of 3 grams, three times per day, between meals. Overall, the patients of both diagnostic types who received Ltryptophan showed greater improvement on both the Manic State Rating Scale and the Brief Psychiatric Rating Scale as compared to those who received only lithium, but this was considered to be more evident in the schizoaffective patients. However, the relatively liberal use of as needed neuroleptic medication makes it difficult to interpret this finding.
Bupropion. There is extensive evidence that bupropion is an effective antidepressant for unipolar and bipolar depression . It produces few side effects, and, of particular importance, has not been noted to produce an exacerbation of psychotic symptoms. This possibility had been anticipated because bupropion is an effective inhibitor of dopamine uptake and has few other known actions (Cooper, Hester, and Maxwell 1980) . A recent investigation of the antidepressant action of bupropion suggests a significant difference between schizoaffective patients and those with major affective disorder. Goode and Manning (1983) treated nine schizoaffective depressed patients (RDC) with bupropion alone at a dose of 750 mg/day. Three of the patients experienced severe exacerbations of schizophrenic-type symptoms that required their discontinuation from the study. The other six patients did not do particularly well. Eleven other patients received bupropion plus haloperidol; five were judged very improved and four moderately improved. If it can be confirmed that bupropion alone may produce antidepressant effects in major depression with psychotic symptoms, but is ineffective in schizoaffective depression except for producing an exacerbation of schizophrenic-type symptoms, this drug could become a useful tool for identifying biological differences between these types of patients.
Summary
Based on our review of the literature, the following major conclusions concerning the chemotherapy of schizoaffective disorders and affective disorders can be drawn:
• Lithium carbonate and neuroleptics, alone or in combination, are effective treatments for mania and schizoaffective mania and produce improvement in mood as well as psychotic symptoms.
• Schizoaffective manic patients require a significantly longer time than manics to respond to these medications. This may be an indication of a qualitative or a quantitative difference between the two types of disorders.
• Schizoaffective depressed patients may respond to either neuroleptics or antidepressants, or the combination, but their course is much less predictable than that of patients with major depressive disorder. • Lithium 'carbonate is an effective prophylactic treatment of schizoaffective disorder, with results at least as good as in bipolar affective illness. This result suggests that there is overlap in the etiology of schizoaffective and affective disorders.
Despite the abundance of studies we have reviewed, there is still considerable need for further studies which include a large series of subjects diagnosed by RDC or other criteria which provide for the differentiation of subtypes of schizoaffective disorder. Ideally, these studies should include manic, major depression, and schizophrenic patients as comparison groups and use random assignment to treatment if more than one treatment is to be compared. Carbamazepine or Ltryptophan, with or without lithium, which have been reported to have some efficacy in the major affective disorders, could be useful agents to include in some such studies. Prophylactic studies with lithium, carbamazepine, L-tryptophan, 5-hydroxyrryptophan, or placebo with a large cohort of schizoaffective depressed and manic patients, studied over a long period of time and compared with pure bipolar patients, should identify patients who are nonresponders. The nonresponders would represent a potential group of subjects for further study of the possibility that some schizoaffective patients are more like schizophrenics or are a unique psychosis.
